Filing Details

Accession Number:
0001140361-17-047823
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-29 17:07:50
Reporting Period:
2017-12-29
Accepted Time:
2017-12-29 17:07:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1402856 Jr Kent R Mcgaughy C/O Cpmg, Inc.
2000 Mckinney Ave, Ste 2125
Dallas TX 75201
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2017-12-29 17,000 $28.47 2,912,523 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 4,591 Indirect By Lagos Trust
Class A Common Stock 280 Indirect By Traweek Children's Trust
Class A Common Stock 2,739 Indirect See footnote
Class A Common Stock 25,004 Direct
Footnotes
  1. These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc.
  2. The Reporting Person is trustee of Lagos Trust.
  3. The Reporting Person is trustee of Traweek Children's Trust.
  4. These shares of Class A common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC.
  5. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  6. This price reflects the weighted average purchase price for open-market purchases on December 29, 2017, within a $1.00 range. The actual prices for these transactions range from $28.40 to $28.50 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4.